Study of High dose Toremifene for metastatic breast cancer after failure of adjuvant therapy of Aromatase Inhibitor

Study of High dose Toremifene for metastatic breast cancer after failure of adjuvant therapy of Aromatase Inhibitor - Study of High dose Toremifene for metastatic breast cancer after failure of adjuvant therapy of Aromatase Inhibitor

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000489

Enrollment

Registered

2006-10-01

Start date

2005-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First line therapy for recurrence or metastatic postmenopausal breast cancer

Interventions

Toremifene 120mg/day for at least 12 weeks until disease progression.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.recurrence or metastatic breast cancer 2.post menopausal woman 3.ER+ and/or PgR+ 4.measurable lesion except for bone metastasis 5.using Aromatase Inhibitor as adjuvant therapy for at least 1 year. 6.normal bone marrow function

Exclusion criteria

Exclusion criteria: 1.brain metastasis 2.bilateral brest cancer 3.male breast cancer 4.severe allergy 5.severe complications

Design outcomes

Primary

Measure	Time frame
Response Rate	—

Secondary

Measure	Time frame
Clinical benefit, Progression-Free Survival, adverse events	—

Countries

Japan

Contacts

Public ContactMasataka Sawaki

Nagoya University of School of Medicine Breast and Endocrine Surgery

sawapi@qc4.so-net.ne.jp052-744-2251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026